Privately-held German firm Immatics Biotechnologies today announced that Cedrik Britten has been appointed as chief medical officer (CMO) effective June 1, 2020.
Trained as a physician, Dr Britten will join Immatics with more than a decade of experience in clinical development including his most recent position as vice president and head of the Oncology Cell Therapy Research Unit at GlaxoSmithKline (LSE: GSK. He will be responsible for the management and global development of Immatics’ clinical pipeline. Prior to GSK, he held various senior positions at BioNTech including vice president for R&D.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze